Adjuvant Fermented Wheat Germ Extract (Avemar<sup>™</sup>) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up

Демидов, Лев В.; Manziuk, Ljudmila V.; Kharkevitch, Galina Y.; Пирогова, Н. А.; Артамонова, Е. В.

doi:10.1089/cbr.2008.0486

Cited by 38 publications

(43 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is currently used as an adjuvant therapy, and its efficacy has been proven in CRC [16] as well as melanoma [17]. Resveratrol is a phytochemical with chemopreventive activity, and its pharmacokinetics has been well studied in human CRC patients [18].…”

Section: Methodsmentioning

confidence: 99%

Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas

et al. 2015

View full text Add to dashboard Cite

Glycolysis and the pentose phosphate pathway (PPP) are preferentially activated in cancer cells. Accumulating evidence indicated the significance of the altered glucose metabolism in cancer, but the implication for oncotherapy remains unclear. Here we report that the synthesis of glycolytic and PPP enzymes is almost ubiquitously augmented in colorectal carcinoma (CRC) specimens. The mammalian target of rapamycin (mTOR) inhibitor INK128 (300 nM) and phytochemical Avemar (1 mg/ml) inhibited the synthesis of PPP enzymes in CRC cell lines. INK128 (150-600 nM) and resveratrol (75-300 μM) inhibited aerobic glycolysis in the cell lines. INK128 (300 nM) and Avemar (1 mg/ml) decreased the NADPH/NADP⁺ ratio as well as the GSH/GSSG ratio in the cell lines. Finally, per os administration of INK128 (0.8 mg/kg) or Avemar (1 g/kg) suppressed tumor growth and delayed tumor formation by transplantable CRC specimens derived from patients. Taken together, pharmacological inhibition of the mTOR-PPP axis is a promising therapeutic strategy against CRCs.

show abstract

Section: Methodsmentioning

confidence: 99%

Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The mean overall survival of the FWGE group was 66.2 months versus 44.7 months in the control group. 10 Chemotherapy-Related Infection FWGE appears to enhance immunity and resistance to infection in children undergoing cancer treatment. In an openlabel, matched-pair, pilot clinical trial, doctors treated 22 patients with chemotherapy or chemotherapy plus daily FWGE.…”

Section: Melanomamentioning

confidence: 99%

Current Controversies in Nutrition: Fermented Wheat Germ Extract—An Adjunct Treatment for Cancer?

ChallemJack

2012

Alternative and Complementary Therapies

View full text Add to dashboard Cite

“…After a 7-yr-long follow-up period of the treated patients, log-rank analysis still showed significant differences in favor of Avemar group regarding both progression free survival (PFS) and overall survival (OS). Namely, mean PFSs were 55.8 mo vs. 29.9 mo, and the mean OSs were 66.2 mo vs. 44.7 mo in the Avemar and control groups, respectively (31). In the third study, a cohort of 55 evaluable head and neck cancer patients were studied.…”

Section: Clinical Datamentioning

confidence: 99%

Avemar (Wheat Germ Extract) in Cancer Prevention and Treatment

Telekes

Hegedüs

Chae

et al. 2009

Nutrition and Cancer

View full text Add to dashboard Cite

Many healthy foods are derived from wheat germ. The molecular composition of these products, however, greatly differs as shown by normal-phase HPLC-mass spectrometry analysis; thus, experimental data obtained by one of them is not necessarily true for the other. Avemar is a nontoxic wheat germ extract registered as a special nutriment for cancer patients in Hungary. It shows potent anticancer activity on cell lines by deeply interfering with glucose metabolism and affecting expressions of several kinases. In in vivo experimental models, Avemar is also effective by enhancing the activity of the immune system such as stimulating NK cell activity (by reducing MHC I molecule expression), enhancing TNF secretion of the macrophages, increasing ICAM 1 molecule expression on the vascular endothelial cells. All of these lead to apoptosis of tumor cells. The wide range of biological activity of Avemar probably cannot be explained by only one active ingredient. Since there are numerous experimental data and the clinical benefit repeatedly confirmed Avemar can be one of the most potent and best researched food supplements available for cancer patients.

show abstract

Adjuvant Fermented Wheat Germ Extract (Avemar^™) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up

Abstract: The inclusion of Avemar into the adjuvant protocols of high-risk skin melanoma patients is highly recommended.

Cited by 38 publications

References 18 publications

Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas

Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas

Current Controversies in Nutrition: Fermented Wheat Germ Extract—An Adjunct Treatment for Cancer?

Avemar (Wheat Germ Extract) in Cancer Prevention and Treatment

Contact Info

Product

Resources

About

Adjuvant Fermented Wheat Germ Extract (Avemar™) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up

Abstract: The inclusion of Avemar into the adjuvant protocols of high-risk skin melanoma patients is highly recommended.

Cited by 38 publications

References 18 publications

Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas

Augmented Pentose Phosphate Pathway Plays Critical Roles in Colorectal Carcinomas

Current Controversies in Nutrition: Fermented Wheat Germ Extract—An Adjunct Treatment for Cancer?

Avemar (Wheat Germ Extract) in Cancer Prevention and Treatment

Contact Info

Product

Resources

About

Adjuvant Fermented Wheat Germ Extract (Avemar^™) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up